European Vaccine Initiative (EVI)

The European Vaccine Initiative (EVI) is a non-profit Product Development Partnership supporting the development of vaccines for diseases of poverty by bridging conceptual and operational gaps in translational research. EVI supports the strengthening of the vaccine R&D infrastructure in Europe, harmonisation, knowledge sharing and aligning of major vaccine R&D stakeholders. Areas of EVI's expertise in vaccine development from preclinical to clinical proof-of-concept include process development, development of quality control assays, optimisation of GMP production, selection of the most appropriate delivery system, development of formulation with adjuvants and early stage clinical development. EVI has extensive experience of more than a decade in coordinating in large scale infrastructure and collaborative research projects funded by the EC and other funding agencies during the last decade.

Role of EVI in VAC2VAC

EVI is the project coordinator of VAC2VAC and is in charge of administrative-financial management, dissemination and communication. Moreover, EVI will contribute to the development, dissemination and implementation of Standard Operating Procedures (SOPs) for key assays; contribute to development and reference preparations and common reagents, contribute to the harmonisation and standardisation of methods and assays. Additionally, EVI will also contribute to the preparation of a roadmap and engagement of regulatory bodies.

Partner representatives

 
Hilde DepraetereHilde Depraetere has a PhD in Biochemistry from KULeuven, and more than 15 years experience in regulatory affairs (vaccines), preclinical and assay development and research management in several private and public organisations.  Her professional career commenced in 1995 at the University of Leuven.  Before joining EVI, Hilde worked as a Senior Regulatory Affairs Consultant for European Drug Regulatory Affairs Consulting (EUDRAC) GmbH, prior to which she was from 2006 - 2013 in the global regulatory department of GlaxoSmithKline Biologicals (GSK) in Belgium, Thrombogenics, in Belgium and RSR Ltd., a diagnostic company in Cardiff, Wales.